CDXS Codexis

Codexis to Hold Second Quarter 2019 Conference Call on August 6

Codexis to Hold Second Quarter 2019 Conference Call on August 6

REDWOOD CITY, Calif., July 30, 2019 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that it will report second quarter 2019 financial results after market close on Tuesday, August 6, 2019. Codexis management will hold an investment community conference call at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss financial results and provide a company update. A slide presentation featuring an updated product pipeline to accompany the conference call commentary will be available on the Investors section of the company’s website at .



Live Call:U.S.855 890 8665 
 International720 634 2938 
 Passcode1159525 
    
Live Webcast:  
 The webcast will be archived for 90 days. 
    
Replay:U.S.855 859 2056 
 International404 537 3406 
 Passcode1159525 
 The replay will be available for 48 hours 
   

About Codexis, Inc.

Codexis is a leading protein engineering company that applies its proprietary CodeEvolver® technology to develop proteins for a variety of applications, including as biocatalysts for the commercial manufacture of pharmaceuticals, fine chemicals and industrial enzymes, and enzymes as biotherapeutics and for use in molecular diagnostics. Codexis’ proven technology enables improvements in protein performance, meeting customer needs for rapid, cost-effective and sustainable manufacturing in multiple commercial-scale implementations of biocatalytic processes. For more information, see

CONTACT

Investors

LHA Investor Relations

Jody Cain, 310 691 7100

EN
30/07/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Codexis

 PRESS RELEASE

Codexis Achieves ISO 9001:2015 Certification

Codexis Achieves ISO 9001:2015 Certification REDWOOD CITY, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Codexis Inc. (Nasdaq: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, announced today that it has earned its ISO 9001:2015 certification. The official certification reflects Codexis’s dedication to delivering manufacturing excellence by applying a high standard of quality assurance throughout all of its processes, including research and development, product manufacturing and testing, delivery, support, and customer service. “Quality ...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: December 1, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Codexis Announces Signing of Lease for GMP Manufacturing Facility

Codexis Announces Signing of Lease for GMP Manufacturing Facility REDWOOD CITY, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, today announced that it has signed a lease for a 34,000 square foot GMP manufacturing facility in Hayward, California. The multi-purpose facility will allow Codexis to expand its internal capabilities into GMP manufacturing of siRNA and other oligonucleotides using its ECO Synthesis platform. The company expects to begin modific...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch